文献速递白血病贫血与红细胞疾病

环磷酰胺单药治疗T细胞大颗粒淋巴细胞白血病的疗效及停药后疗效维持分析

[Analysis of treatment response and post-discontinuation efficacy maintenance of cyclophosphamide monotherapy in T-cell large granular lymphocytic leukemia].
PubMed 文献 · Zhonghua Xue Ye Xue Za Zhi · 2025-01-01

回顾性分析37例接受环磷酰胺单药口服的T细胞大颗粒淋巴细胞白血病患者,可评价疗效的36例中25例(69.4%)达血液学缓解,中位缓解时间2.0个月;25例缓解者中24例停药,中位随访39.0个月,12个月和36个月无治疗缓解率分别为(90.87±6.16)%和(75.72±11.04)%。

要点

  • 37例T-LGLL患者接受环磷酰胺50~100 mg/d口服,可评价36例中25例(69.4%)达血液学缓解。
  • 初治组与复发/难治组血液学缓解率差异无统计学意义(68.5%对66.7%,P=0.589)。
  • 24例停药患者中位随访39.0个月,12个月和36个月TFR率分别为(90.87±6.16)%和(75.72±11.04)%。

核心结论

  • 环磷酰胺单药口服可以有效治疗T-LGLL,且患者停药后有望维持长期无治疗缓解。

研究设计与样本

  • 回顾性收集2019年6月至2024年3月中国医学科学院血液病医院再生医学诊疗中心收治的37例接受环磷酰胺单药口服治疗的T-LGLL患者临床资料,分析临床特点、疗效及长期无治疗缓解情况。

主要发现

  • 37例患者中位年龄60(37~86)岁,男22例(59.5%);贫血30例(81.1%),符合继发性纯红细胞再生障碍标准28例(75.7%),粒细胞减少或缺乏15例(40.5%),淋巴细胞计数增多11例(29.7%),血小板减少3例(8.1%)。
  • 初治组16例(43.2%),复发/难治组21例(56.8%);可评价疗效的36例中达血液学缓解25例(69.4%),中位达血液学缓解时间2.0(0.7~7.0)个月。
  • 初治组与复发/难治组血液学缓解率差异无统计学意义(68.5%对66.7%,P=0.589)。
  • 25例达血液学缓解者中24例已停用环磷酰胺,中位随访39.0(8.0~56.0)个月,停药后中位无治疗缓解期未达到,预估12个月无治疗缓解率为(90.87±6.16)%,36个月为(75.72±11.04)%。
  • 初治组与复发/难治组环磷酰胺停药后无治疗缓解差异无统计学意义(P=0.451)。

关键数值与推荐

  • 所有患者符合治疗指征,接受环磷酰胺50~100 mg/d口服。
  • 可评价疗效的36例患者中达血液学缓解25例(69.4%),中位达血液学缓解时间2.0(0.7~7.0)个月。
  • 初治组与复发/难治组血液学缓解率分别为68.5%和66.7%,差异无统计学意义(P=0.589)。
  • 停药后预估12个月无治疗缓解率为(90.87±6.16)%,36个月为(75.72±11.04)%。

临床怎么用

  • 原文结论为环磷酰胺单药口服可以有效治疗T-LGLL,且患者停药后有望维持长期无治疗缓解。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Objective: To evaluate the efficacy of cyclophosphamide in patients with T-cell large granular lymphocytic leukemia (T-LGLL) and the maintenance of treatment-free remission (TFR) following drug discontinuation. Methods: Clinical data were collected from 37 patients with T-LGLL who received oral cyclophosphamide at the Regenerative Medicine Clinic of the Institute of Hematology and Blood Diseases Hospital between June 2019 and March 2024. Patient clinical characteristics, treatment efficacy, and long-term TFR were analyzed. Results: The median age of the 37 patients was 60 years (range: 37-86), and 22 (59.5%) were male. Anemia was observed in 30 patients (81.1%), and 28 (75.7%) met the diagnostic criteria for secondary pure red cell aplasia. Neutropenia occurred in 15 patients (40.5%), lymphocytosis in 11 (29.7%), and thrombocytopenia in three (8.1%). Sixteen patients (43.2%) had not received prior immunosuppressive therapy (treatment-naive group), while 21 patients (56.8%) were refractory to or had relapsed after immunosuppressive treatment (refractory/relapsed group). All patients met the treatment criteria and received oral cyclophosphamide at doses of 50-100 mg/day. Among the 36 evaluable patients, hematologic remission was achieved in 25 (69.4%), with a median time of 2.0 months (range: 0.7-7.0). There was no statistically significant difference in remission rates between the treatment-naive and refractory/relapsed groups (68.5% vs. 66.7%, P=0.589). Among the 25 patients who achieved hematologic remission, 24 discontinued cyclophosphamide. With a median follow-up of 39.0 months (range: 8.0-56.0), the median TFR duration was not reached. The estimated TFR rates were (90.87± 6.16) % at 12 months and (75.72±11.04) % at 36 months. No significant difference in TFR was observed between the treatment-naive and refractory/relapsed groups (P=0.451) . Conclusion: Oral cyclophosphamide is effective in the treatment of T-LGLL, and patients may maintain long-term TFR following drug discontinuation. 目的: 探索环磷酰胺单药治疗T细胞大颗粒淋巴细胞白血病(T-LGLL)的疗效及停药后疗效维持情况。 方法: 收集2019年6月至2024年3月中国医学科学院血液病医院再生医学诊疗中心收治的37例接受环磷酰胺单药口服治疗的T-LGLL患者临床资料,分析其临床特点、疗效及长期无治疗缓解(TFR)情况。 结果: 37例T-LGLL患者中位年龄为60(37~86)岁,男22例(59.5%)。30例(81.1%)表现为贫血,28例(75.7%)符合继发性纯红细胞再生障碍标准,15例(40.5%)出现粒细胞减少或缺乏,11例(29.7%)存在淋巴细胞计数增多,3例(8.1%)血小板减少。既往未接受过免疫抑制治疗的16例(43.2%)患者为初治组;免疫抑制治疗复发或无效的21例(56.8%)患者为复发/难治组。所有患者符合治疗指征,接受环磷酰胺(50~100)mg/d口服,可评价疗效的36例患者中达血液学缓解25例(69.4%),中位达血液学缓解时间为2.0(0.7~7.0)个月;初治组与复发/难治组血液学缓解率差异无统计学意义(68.5%对66.7%,P=0.589)。25例达血液学缓解的患者中,24例已停用环磷酰胺,中位随访时间39.0(8.0~56.0)个月,环磷酰胺停药后中位TFR期未达到,预估12个月TFR率为(90.87±6.16)%,36个月TFR率为(75.72±11.04)%;(初)治组与复发/难治组环磷酰胺的TFR差异无统计学意义(P=0.451)。 结论: 环磷酰胺单药口服可以有效治疗T-LGLL,且患者停药后有望维持长期TFR。.

来源:Zhonghua Xue Ye Xue Za Zhi,查看原文。版权归原作者所有。

引用

  1. Zhang LL, Tian LZ, Pan H, et al. [Analysis of treatment response and post-discontinuation efficacy maintenance of cyclophosphamide monotherapy in T-cell large granular lymphocytic leukemia]. Zhonghua Xue Ye Xue Za Zhi. 2025. PMID: 40887419. doi:10.3760/cma.j.cn121090-20241024-00416

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。